University of Utah at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Utah brings 1 presentation to ASH 2026 in New Orleans. Its program spans BCMA-targeted bispecific antibodies for myeloma and treatment decisions in systemic mastocytosis. It also looks at how inflammation around birth affects the fitness of blood stem cells.
| Organization | ASH 2026 Attendance |
|---|---|
University of Utah Salt Lake City, UT | |
Public research university in Salt Lake City with the University of Utah Health system and Huntsman Cancer Institute. | Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Symposium Fri Dec 11 7:00pm–10:00pm Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis Recognizing the full symptom burden of non-advanced systemic mastocytosis, judging disease control, and deciding when to escalate to disease-directed therapy. Talk The Impact of Perinatal Inflammation on HSC Fitness How fetal blood stem and progenitor cells respond to inflammation before birth, leaving lasting marks on the immune system after birth. |
Instantly find 20 buyers from University of Utah
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction